Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
IDentaIDTA 45 Earnings Yield (Joel Greenblatt) % is 21.93% as of Jun. 2026, which is 198% above its 10-year median of 7.37. GuruFocus rates IDTA with a GF Score™ of 45/100 and a GF Value™ of $0.36 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 212 Medical Diagnostics & Research companies, IDenta ranks better than 98.11% on this metric.
IDenta's Enterprise Value for the quarter that ended in Jun. 2026 was $1.09 Mil.
IDenta's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 was $0.24 Mil. IDenta's Earnings Yield (Joel Greenblatt) for the quarter that ended in Jun. 2026 was 21.93%.
The historical rank and industry rank for IDenta's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:
IDTA'
s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: -2.26 Med: 7.37 Max: 43.17
Current: 18.59
During the past 8 years, the highest Earnings Yield (Joel Greenblatt) of IDenta was 43.17%. The lowest was -2.26%. And the median was 7.37%.
IDTA's Earnings Yield (Joel Greenblatt) % is ranked better than 98.11% of 212
companies
in the Medical Diagnostics & Research industry
Industry Median: -0.175
vs IDTA: 18.59
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. IDenta's Forward Rate of Return (Yacktman) % for the quarter that ended in Jun. 2026 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.
Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.
Be Aware
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
IDenta Earnings Yield (Joel Greenblatt) % Related Terms
IDenta Earnings Yield (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for IDenta's Earnings Yield (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, IDenta's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
IDenta Earnings Yield (Joel Greenblatt) % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, IDenta's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where IDenta's Earnings Yield (Joel Greenblatt) % falls into.
In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.
IDentas Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Dec. 2025 is calculated as
IDenta's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.24 Mil.
What does a Earnings Yield (Joel Greenblatt) % of 21.93% mean?
IDenta (IDTA) has a Earnings Yield (Joel Greenblatt) % of 21.93% as of Jun. 2026. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on IDenta and its competitors. This is 198% above median its historical median of 7.37. According to the industry distribution chart, IDenta ranks #4 out of 212 companies in the Medical Diagnostics & Research industry, placing it in the top 1.9%.
Is IDenta's Earnings Yield (Joel Greenblatt) % too high?
IDenta's current Earnings Yield (Joel Greenblatt) % of 21.93% is 198% above median its 10-year median of 7.37. Based on the distribution chart, IDenta ranks #4 out of 212 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, IDenta has a GF Score™ of 45/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does IDenta's Earnings Yield (Joel Greenblatt) % compare to PRPH and NSTM?
According to the Medical Diagnostics & Research industry distribution chart, IDenta ranks #4 out of 212 companies for Earnings Yield (Joel Greenblatt) %. This places IDenta in the top 2% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings Yield (Joel Greenblatt) % for a Medical Diagnostics & Research company?
A good Earnings Yield (Joel Greenblatt) % depends on the Medical Diagnostics & Research industry context. However, Earnings Yield (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings Yield (Joel Greenblatt) % mean?
A high Earnings Yield (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on IDenta and its competitors. IDenta's current Earnings Yield (Joel Greenblatt) % is 21.93%, which is 198% above median its own 10-year median of 7.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IDenta stock overvalued right now?
Based on GuruFocus' analysis, IDenta (IDTA) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.36, compared to a current price of $0.30 — trading 16.7% below its estimated fair value. The current Earnings Yield (Joel Greenblatt) % is 21.93%, which is 198% above median its 10-year median of 7.37. IDenta's overall GF Score™ is 45/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings Yield (Joel Greenblatt) % calculated?
Earnings Yield (Joel Greenblatt) % is calculated from a company's financial statements. For IDenta (IDTA), the current Earnings Yield (Joel Greenblatt) % is 21.93% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is IDenta (IDTA) Overvalued in 2026?
Based on GuruFocus' analysis, IDenta stock appears to be undervalued.
The current stock price of $0.30 is trading 16.7% below its estimated GF Value™ of $0.36.
GuruFocus considers IDenta to be Modestly Undervalued.
Key valuation signals for IDTA:
Earnings Yield (Joel Greenblatt) %: 21.93% (198% above median its 10-year median of 7.37)
GF Value™: $0.36 vs. price of $0.30 (16.7% below fair value)
No single metric tells the full story. See the IDTA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
IDenta Corp is a detection and forensic science company. The firm, through its subsidiary, is engaged in the business of developing products to test for the presence of illegal drugs and explosives for law enforcement agencies, ports and border crossings, shipping hubs, and other organizations. Its product portfolio includes Drug testing kits, Explosive testing kits, Forensic products, Urine drug testing and others. The company currently sells its products to law enforcement organizations in the following countries: Indonesia, Argentina, Poland, France, USA, Spain, India, the United Kingdom, Ghana, Nigeria, Australia, Russia, Israel, Canada, Germany, Italy, and Portugal. The company also sells to retail markets in the United States, Italy, and South Africa.
45GF Score
Get the complete analysis for IDTA
Earnings Yield (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IDTA has been successfully added to your 
